![Pharmacokinetic and Immunological Considerations for Expanding the Therapeutic Window of Next-Generation Antibody–Drug Conjugates | SpringerLink Pharmacokinetic and Immunological Considerations for Expanding the Therapeutic Window of Next-Generation Antibody–Drug Conjugates | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs40259-018-0302-5/MediaObjects/40259_2018_302_Fig1_HTML.png)
Pharmacokinetic and Immunological Considerations for Expanding the Therapeutic Window of Next-Generation Antibody–Drug Conjugates | SpringerLink
![On the use of DNA as a linker in antibody-drug conjugates: synthesis, stability and in vitro potency | Scientific Reports On the use of DNA as a linker in antibody-drug conjugates: synthesis, stability and in vitro potency | Scientific Reports](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41598-020-64518-y/MediaObjects/41598_2020_64518_Fig1_HTML.png)
On the use of DNA as a linker in antibody-drug conjugates: synthesis, stability and in vitro potency | Scientific Reports
![Chemotherapy payload of anti-insoluble fibrin antibody-drug conjugate is released specifically upon binding to fibrin | Scientific Reports Chemotherapy payload of anti-insoluble fibrin antibody-drug conjugate is released specifically upon binding to fibrin | Scientific Reports](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41598-018-32601-0/MediaObjects/41598_2018_32601_Fig1_HTML.png)
Chemotherapy payload of anti-insoluble fibrin antibody-drug conjugate is released specifically upon binding to fibrin | Scientific Reports
![Cleavable linkers in antibody–drug conjugates - Chemical Society Reviews (RSC Publishing) DOI:10.1039/C8CS00676H Cleavable linkers in antibody–drug conjugates - Chemical Society Reviews (RSC Publishing) DOI:10.1039/C8CS00676H](https://pubs.rsc.org/image/article/2019/CS/c8cs00676h/c8cs00676h-f1_hi-res.gif)
Cleavable linkers in antibody–drug conjugates - Chemical Society Reviews (RSC Publishing) DOI:10.1039/C8CS00676H
![Comparison of Analytical Methods for Antibody-Drug Conjugates Produced by Chemical Site-Specific Conjugation: First-Generation AJICAP.,Analytical Chemistry - X-MOL Comparison of Analytical Methods for Antibody-Drug Conjugates Produced by Chemical Site-Specific Conjugation: First-Generation AJICAP.,Analytical Chemistry - X-MOL](https://xpic.x-mol.com/20190904%2F10.1021_acs.analchem.9b02192.jpg)
Comparison of Analytical Methods for Antibody-Drug Conjugates Produced by Chemical Site-Specific Conjugation: First-Generation AJICAP.,Analytical Chemistry - X-MOL
![Harnessing a catalytic lysine residue for the one-step preparation of homogeneous antibody-drug conjugates | Nature Communications Harnessing a catalytic lysine residue for the one-step preparation of homogeneous antibody-drug conjugates | Nature Communications](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41467-017-01257-1/MediaObjects/41467_2017_1257_Fig1_HTML.jpg)
Harnessing a catalytic lysine residue for the one-step preparation of homogeneous antibody-drug conjugates | Nature Communications
Chemotherapy payload of anti-insoluble fibrin antibody-drug conjugate is released specifically upon binding to fibrin
![Frontiers | Antibody-Drug Conjugates (ADC) Against Cancer Stem-Like Cells (CSC)—Is There Still Room for Optimism? | Oncology Frontiers | Antibody-Drug Conjugates (ADC) Against Cancer Stem-Like Cells (CSC)—Is There Still Room for Optimism? | Oncology](https://www.frontiersin.org/files/MyHome%20Article%20Library/445531/445531_Thumb_400.jpg)
Frontiers | Antibody-Drug Conjugates (ADC) Against Cancer Stem-Like Cells (CSC)—Is There Still Room for Optimism? | Oncology
![Strategies and challenges for the next generation of antibody–drug conjugates | Nature Reviews Drug Discovery Strategies and challenges for the next generation of antibody–drug conjugates | Nature Reviews Drug Discovery](https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fnrd.2016.268/MediaObjects/41573_2017_Article_BFnrd2016268_Fig1_HTML.jpg)
Strategies and challenges for the next generation of antibody–drug conjugates | Nature Reviews Drug Discovery
![Proof of site-specificity of antibody-drug conjugates produced by chemical conjugation technology: AJICAP first generation - ScienceDirect Proof of site-specificity of antibody-drug conjugates produced by chemical conjugation technology: AJICAP first generation - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S1570023219317167-ga1.jpg)